Showing 641-650 of 2075 results for "".
The Science Driving Topicals Into the Future
https://practicaldermatology.com/topics/psoriasis/the-science-driving-topicals-into-the-future/19721/On the therapeutic front, one topic Neal Bhatia, MD is paying particularly close attention to is recent advances in vehicle science, which offer novel and intriguing strategies to improve delivery of topical applications to and through the skin.Targeting Tech Neck
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/targeting-tech-neck/19617/Today’s tech-obsessed population is always looking down at devices, creating lines and wrinkles in the neck. Kim Nichols, MD describes the problem of Tech Neck and the regimen she uses to treat it.Improving Outcomes with Neuromodulators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/improving-outcomes-with-neuromodulators/18521/Joel L. Cohen, MD offers treatment tips for best, natural outcomes with neuromodulator injections. He also discusses how injecting toxins prior to resurfacing or prior to filler injections can improve results and duration of effects.Innovation in Dermatology Entrepreneurship
https://practicaldermatology.com/topics/practice-management/innovation-in-dermatology-entrepreneurship/18912/Entrepreneurship in dermatology is "in a good spot," says William Ju, MD, President of Advancing Innovation in Dermatology. Dermatology is a high-growth field, supported by patient demand and globalization and scientific advancements.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.GEP Testing for Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/series/updates-in-skin-cancer/gep-testing-for-cutaneous-squamous-cell-carcinoma/35599/Emily Ruiz, MD, MPH, FAAD, director of the High-Risk Cancer Clinic at Dana-Farber Cancer Institute, discusses utilizing gene expression profiling (GEP) to risk stratify tumors in cutaneous squamous cell carcinoma patients.Shifting Paradigms on Lentigo Maligna
https://practicaldermatology.com/conferences/maui-derm-2024/shifting-paradigms-on-lentigo-maligna/20255/According to Ashfaq Marghoob, MD, current research supports individualizing treatment of lentigo maligna (LM) based on what is the best therapeutic option, from active surveillance to surgery to radiation to imiquimod.Choosing the Right Wound Dressing
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/choosing-the-right-wound-dressing/33017/Dennis Orgill, MD, PhD, a reconstructive plastic surgeon at Brigham and Women's Hospital in Boston, discusses the importance of choosing the right dressing for wound care at Masterclasses in Dermatology 2025 in Sarasota.SCALE 2024: Dr. Michael Gold Recaps the Show and Previews 2025
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michael-gold-recaps-show-and-previews-2025/26751/Michael Gold, MD, FAAD, Course Co-Director for Music City SCALE, discusses the growth of the event over the years, highlights from 2024, and what to expect next year.When and How to Use Ancillary Testing
https://practicaldermatology.com/programs/practical-dermatology-updates-in-skin-cancer/when-and-how-to-use-ancillary-testing/35598/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses when a dermatopathologist decides to use ancillary testing for melanoma, how that impacts final diagnosis, and how it can guide treatment decisions.